nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRIN2C—nerve—skin cancer	0.0208	0.187	CbGeAlD
Acamprosate—GRIN2B—nerve—skin cancer	0.0164	0.148	CbGeAlD
Acamprosate—GRIN2A—nerve—skin cancer	0.0143	0.129	CbGeAlD
Acamprosate—GRM5—female reproductive system—skin cancer	0.00774	0.0696	CbGeAlD
Acamprosate—GRM5—head—skin cancer	0.00646	0.0582	CbGeAlD
Acamprosate—GRIN2C—head—skin cancer	0.00492	0.0443	CbGeAlD
Acamprosate—SLC36A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00479	0.0417	CbGpPWpGaD
Acamprosate—GRIN2D—head—skin cancer	0.00458	0.0412	CbGeAlD
Acamprosate—GRIN3A—head—skin cancer	0.0043	0.0387	CbGeAlD
Acamprosate—GRIN1—head—skin cancer	0.00408	0.0367	CbGeAlD
Acamprosate—SLC36A1—female reproductive system—skin cancer	0.00405	0.0364	CbGeAlD
Acamprosate—GRIN2B—head—skin cancer	0.00389	0.035	CbGeAlD
Acamprosate—GRIN2A—head—skin cancer	0.0034	0.0306	CbGeAlD
Acamprosate—SLC36A1—head—skin cancer	0.00338	0.0304	CbGeAlD
Acamprosate—GRIN1—EPHB-mediated forward signaling—RASA1—skin cancer	0.00303	0.0263	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—RASA1—skin cancer	0.00295	0.0257	CbGpPWpGaD
Acamprosate—GABRB3—connective tissue—skin cancer	0.00279	0.0251	CbGeAlD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.0026	0.0226	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00242	0.0211	CbGpPWpGaD
Acamprosate—SLC36A1—lymph node—skin cancer	0.00237	0.0213	CbGeAlD
Acamprosate—GRIN2C—Post NMDA receptor activation events—BRAF—skin cancer	0.00214	0.0186	CbGpPWpGaD
Acamprosate—GABRG2—head—skin cancer	0.00214	0.0193	CbGeAlD
Acamprosate—SLC36A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00214	0.0186	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTCH2—skin cancer	0.00208	0.0181	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—BRAF—skin cancer	0.00199	0.0173	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00199	0.0173	CbGpPWpGaD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00197	0.0172	CbGpPWpGaD
Acamprosate—GABRB3—female reproductive system—skin cancer	0.00197	0.0177	CbGeAlD
Acamprosate—GRIN1—Spinal Cord Injury—CSPG4—skin cancer	0.00193	0.0167	CbGpPWpGaD
Acamprosate—GABRA1—head—skin cancer	0.00189	0.017	CbGeAlD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00184	0.016	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00173	0.0151	CbGpPWpGaD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.00169	0.0147	CbGpPWpGaD
Acamprosate—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00168	0.0146	CbGpPWpGaD
Acamprosate—GABRB3—head—skin cancer	0.00165	0.0148	CbGeAlD
Acamprosate—GRIN2A—Post NMDA receptor activation events—BRAF—skin cancer	0.00164	0.0142	CbGpPWpGaD
Acamprosate—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00156	0.0136	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—RASA1—skin cancer	0.00156	0.0136	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—RASA1—skin cancer	0.00152	0.0132	CbGpPWpGaD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00151	0.0131	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—MC1R—skin cancer	0.0015	0.0131	CbGpPWpGaD
Acamprosate—GRIN1—Post NMDA receptor activation events—BRAF—skin cancer	0.00143	0.0124	CbGpPWpGaD
Acamprosate—GRIN2B—Post NMDA receptor activation events—BRAF—skin cancer	0.00139	0.0121	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00131	0.0114	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—RHOU—skin cancer	0.00129	0.0112	CbGpPWpGaD
Acamprosate—Hyponatraemia—Docetaxel—skin cancer	0.00129	0.00167	CcSEcCtD
Acamprosate—Visual impairment—Temozolomide—skin cancer	0.00129	0.00167	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.00129	0.00166	CcSEcCtD
Acamprosate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00128	0.0112	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.00128	0.0111	CbGpPWpGaD
Acamprosate—Ill-defined disorder—Bleomycin—skin cancer	0.00128	0.00165	CcSEcCtD
Acamprosate—Anaemia—Bleomycin—skin cancer	0.00128	0.00165	CcSEcCtD
Acamprosate—Diarrhoea—Vemurafenib—skin cancer	0.00127	0.00164	CcSEcCtD
Acamprosate—Migraine—Docetaxel—skin cancer	0.00127	0.00164	CcSEcCtD
Acamprosate—Urticaria—Imiquimod—skin cancer	0.00126	0.00163	CcSEcCtD
Acamprosate—Abdominal pain—Imiquimod—skin cancer	0.00125	0.00162	CcSEcCtD
Acamprosate—Body temperature increased—Imiquimod—skin cancer	0.00125	0.00162	CcSEcCtD
Acamprosate—Tinnitus—Temozolomide—skin cancer	0.00125	0.00161	CcSEcCtD
Acamprosate—Malaise—Bleomycin—skin cancer	0.00124	0.00161	CcSEcCtD
Acamprosate—Haemoglobin—Fluorouracil—skin cancer	0.00124	0.0016	CcSEcCtD
Acamprosate—Leukopenia—Bleomycin—skin cancer	0.00124	0.0016	CcSEcCtD
Acamprosate—Rhinitis—Fluorouracil—skin cancer	0.00124	0.0016	CcSEcCtD
Acamprosate—Haemorrhage—Fluorouracil—skin cancer	0.00123	0.00159	CcSEcCtD
Acamprosate—Dizziness—Vemurafenib—skin cancer	0.00123	0.00159	CcSEcCtD
Acamprosate—Hypoaesthesia—Fluorouracil—skin cancer	0.00123	0.00158	CcSEcCtD
Acamprosate—Pharyngitis—Fluorouracil—skin cancer	0.00122	0.00158	CcSEcCtD
Acamprosate—Immune system disorder—Temozolomide—skin cancer	0.00121	0.00156	CcSEcCtD
Acamprosate—Cough—Bleomycin—skin cancer	0.0012	0.00156	CcSEcCtD
Acamprosate—Chills—Temozolomide—skin cancer	0.0012	0.00155	CcSEcCtD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.0012	0.0104	CbGpPWpGaD
Acamprosate—Ill-defined disorder—Dactinomycin—skin cancer	0.00119	0.00154	CcSEcCtD
Acamprosate—Anaemia—Dactinomycin—skin cancer	0.00119	0.00154	CcSEcCtD
Acamprosate—Liver function test abnormal—Docetaxel—skin cancer	0.00119	0.00153	CcSEcCtD
Acamprosate—Vomiting—Vemurafenib—skin cancer	0.00118	0.00153	CcSEcCtD
Acamprosate—Alopecia—Temozolomide—skin cancer	0.00118	0.00153	CcSEcCtD
Acamprosate—Dry skin—Docetaxel—skin cancer	0.00118	0.00152	CcSEcCtD
Acamprosate—Chest pain—Bleomycin—skin cancer	0.00118	0.00152	CcSEcCtD
Acamprosate—Myalgia—Bleomycin—skin cancer	0.00118	0.00152	CcSEcCtD
Acamprosate—Orthostatic hypotension—Docetaxel—skin cancer	0.00117	0.00152	CcSEcCtD
Acamprosate—Rash—Vemurafenib—skin cancer	0.00117	0.00151	CcSEcCtD
Acamprosate—Mental disorder—Temozolomide—skin cancer	0.00117	0.00151	CcSEcCtD
Acamprosate—Dermatitis—Vemurafenib—skin cancer	0.00117	0.00151	CcSEcCtD
Acamprosate—Hypersensitivity—Imiquimod—skin cancer	0.00117	0.00151	CcSEcCtD
Acamprosate—Headache—Vemurafenib—skin cancer	0.00116	0.00151	CcSEcCtD
Acamprosate—Malnutrition—Temozolomide—skin cancer	0.00116	0.0015	CcSEcCtD
Acamprosate—Breast disorder—Docetaxel—skin cancer	0.00116	0.0015	CcSEcCtD
Acamprosate—Discomfort—Bleomycin—skin cancer	0.00116	0.0015	CcSEcCtD
Acamprosate—Malaise—Dactinomycin—skin cancer	0.00116	0.0015	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00116	0.0015	CcSEcCtD
Acamprosate—Leukopenia—Dactinomycin—skin cancer	0.00115	0.00149	CcSEcCtD
Acamprosate—Dysgeusia—Temozolomide—skin cancer	0.00114	0.00147	CcSEcCtD
Acamprosate—Asthenia—Imiquimod—skin cancer	0.00114	0.00147	CcSEcCtD
Acamprosate—Confusional state—Bleomycin—skin cancer	0.00114	0.00147	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00113	0.00147	CcSEcCtD
Acamprosate—Anaphylactic shock—Bleomycin—skin cancer	0.00113	0.00146	CcSEcCtD
Acamprosate—Back pain—Temozolomide—skin cancer	0.00113	0.00146	CcSEcCtD
Acamprosate—Pruritus—Imiquimod—skin cancer	0.00112	0.00145	CcSEcCtD
Acamprosate—Infection—Bleomycin—skin cancer	0.00112	0.00145	CcSEcCtD
Acamprosate—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00112	0.00973	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.00111	0.00968	CbGpPWpGaD
Acamprosate—Dysphagia—Docetaxel—skin cancer	0.00111	0.00144	CcSEcCtD
Acamprosate—Nausea—Vemurafenib—skin cancer	0.0011	0.00143	CcSEcCtD
Acamprosate—Thrombocytopenia—Bleomycin—skin cancer	0.0011	0.00143	CcSEcCtD
Acamprosate—Myalgia—Dactinomycin—skin cancer	0.0011	0.00142	CcSEcCtD
Acamprosate—Tremor—Temozolomide—skin cancer	0.00109	0.00141	CcSEcCtD
Acamprosate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00109	0.00948	CbGpPWpGaD
Acamprosate—Alopecia—Fluorouracil—skin cancer	0.00109	0.00141	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00109	0.00946	CbGpPWpGaD
Acamprosate—Diarrhoea—Imiquimod—skin cancer	0.00108	0.0014	CcSEcCtD
Acamprosate—Discomfort—Dactinomycin—skin cancer	0.00108	0.0014	CcSEcCtD
Acamprosate—Angina pectoris—Docetaxel—skin cancer	0.00108	0.0014	CcSEcCtD
Acamprosate—Ill-defined disorder—Temozolomide—skin cancer	0.00108	0.0014	CcSEcCtD
Acamprosate—Anaemia—Temozolomide—skin cancer	0.00108	0.00139	CcSEcCtD
Acamprosate—Anorexia—Bleomycin—skin cancer	0.00107	0.00139	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—SHH—skin cancer	0.00107	0.00932	CbGpPWpGaD
Acamprosate—Agitation—Temozolomide—skin cancer	0.00107	0.00138	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—PTCH2—skin cancer	0.00107	0.00929	CbGpPWpGaD
Acamprosate—Angioedema—Temozolomide—skin cancer	0.00106	0.00137	CcSEcCtD
Acamprosate—Hypotension—Bleomycin—skin cancer	0.00105	0.00136	CcSEcCtD
Acamprosate—Malaise—Temozolomide—skin cancer	0.00105	0.00136	CcSEcCtD
Acamprosate—Dizziness—Imiquimod—skin cancer	0.00105	0.00135	CcSEcCtD
Acamprosate—Vertigo—Temozolomide—skin cancer	0.00105	0.00135	CcSEcCtD
Acamprosate—Infection—Dactinomycin—skin cancer	0.00104	0.00135	CcSEcCtD
Acamprosate—Leukopenia—Temozolomide—skin cancer	0.00104	0.00135	CcSEcCtD
Acamprosate—Palpitations—Temozolomide—skin cancer	0.00103	0.00133	CcSEcCtD
Acamprosate—Thrombocytopenia—Dactinomycin—skin cancer	0.00103	0.00133	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00103	0.00133	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—SMO—skin cancer	0.00102	0.00884	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—PTCH1—skin cancer	0.00102	0.00884	CbGpPWpGaD
Acamprosate—Cough—Temozolomide—skin cancer	0.00102	0.00131	CcSEcCtD
Acamprosate—Paraesthesia—Bleomycin—skin cancer	0.00101	0.00131	CcSEcCtD
Acamprosate—Weight increased—Docetaxel—skin cancer	0.00101	0.00131	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—SCN10A—skin cancer	0.00101	0.00878	CbGpPWpGaD
Acamprosate—Convulsion—Temozolomide—skin cancer	0.00101	0.0013	CcSEcCtD
Acamprosate—Vomiting—Imiquimod—skin cancer	0.00101	0.0013	CcSEcCtD
Acamprosate—Weight decreased—Docetaxel—skin cancer	0.00101	0.0013	CcSEcCtD
Acamprosate—Hypertension—Temozolomide—skin cancer	0.00101	0.0013	CcSEcCtD
Acamprosate—Dyspnoea—Bleomycin—skin cancer	0.001	0.0013	CcSEcCtD
Acamprosate—Anorexia—Dactinomycin—skin cancer	0.001	0.00129	CcSEcCtD
Acamprosate—Rash—Imiquimod—skin cancer	0.001	0.00129	CcSEcCtD
Acamprosate—Dermatitis—Imiquimod—skin cancer	0.000999	0.00129	CcSEcCtD
Acamprosate—Pneumonia—Docetaxel—skin cancer	0.000997	0.00129	CcSEcCtD
Acamprosate—Headache—Imiquimod—skin cancer	0.000993	0.00128	CcSEcCtD
Acamprosate—Anaemia—Fluorouracil—skin cancer	0.000991	0.00128	CcSEcCtD
Acamprosate—Myalgia—Temozolomide—skin cancer	0.000991	0.00128	CcSEcCtD
Acamprosate—Arthralgia—Temozolomide—skin cancer	0.000991	0.00128	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—PTGER4—skin cancer	0.00099	0.0086	CbGpPWpGaD
Acamprosate—Anxiety—Temozolomide—skin cancer	0.000988	0.00128	CcSEcCtD
Acamprosate—GRIN2C—Post NMDA receptor activation events—HRAS—skin cancer	0.000986	0.00857	CbGpPWpGaD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000984	0.00127	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—SCN10A—skin cancer	0.000984	0.00856	CbGpPWpGaD
Acamprosate—Discomfort—Temozolomide—skin cancer	0.000979	0.00127	CcSEcCtD
Acamprosate—Decreased appetite—Bleomycin—skin cancer	0.000979	0.00127	CcSEcCtD
Acamprosate—Acute coronary syndrome—Docetaxel—skin cancer	0.000977	0.00126	CcSEcCtD
Acamprosate—Myocardial infarction—Docetaxel—skin cancer	0.000971	0.00125	CcSEcCtD
Acamprosate—Dry mouth—Temozolomide—skin cancer	0.000969	0.00125	CcSEcCtD
Acamprosate—Stomatitis—Docetaxel—skin cancer	0.000966	0.00125	CcSEcCtD
Acamprosate—Pain—Bleomycin—skin cancer	0.000963	0.00124	CcSEcCtD
Acamprosate—Leukopenia—Fluorouracil—skin cancer	0.00096	0.00124	CcSEcCtD
Acamprosate—Confusional state—Temozolomide—skin cancer	0.000958	0.00124	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000957	0.00124	CcSEcCtD
Acamprosate—Anaphylactic shock—Temozolomide—skin cancer	0.00095	0.00123	CcSEcCtD
Acamprosate—Infection—Temozolomide—skin cancer	0.000944	0.00122	CcSEcCtD
Acamprosate—Nausea—Imiquimod—skin cancer	0.000942	0.00122	CcSEcCtD
Acamprosate—Epistaxis—Docetaxel—skin cancer	0.000934	0.00121	CcSEcCtD
Acamprosate—Thrombocytopenia—Temozolomide—skin cancer	0.00093	0.0012	CcSEcCtD
Acamprosate—Convulsion—Fluorouracil—skin cancer	0.000929	0.0012	CcSEcCtD
Acamprosate—Feeling abnormal—Bleomycin—skin cancer	0.000928	0.0012	CcSEcCtD
Acamprosate—Skin disorder—Temozolomide—skin cancer	0.000923	0.00119	CcSEcCtD
Acamprosate—Hyperhidrosis—Temozolomide—skin cancer	0.000919	0.00119	CcSEcCtD
Acamprosate—GRIN2D—Post NMDA receptor activation events—HRAS—skin cancer	0.000916	0.00797	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000914	0.00795	CbGpPWpGaD
Acamprosate—Chest pain—Fluorouracil—skin cancer	0.000913	0.00118	CcSEcCtD
Acamprosate—Myalgia—Fluorouracil—skin cancer	0.000913	0.00118	CcSEcCtD
Acamprosate—Decreased appetite—Dactinomycin—skin cancer	0.000913	0.00118	CcSEcCtD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000908	0.00789	CbGpPWpGaD
Acamprosate—Anorexia—Temozolomide—skin cancer	0.000906	0.00117	CcSEcCtD
Acamprosate—Discomfort—Fluorouracil—skin cancer	0.000902	0.00117	CcSEcCtD
Acamprosate—Pain—Dactinomycin—skin cancer	0.000898	0.00116	CcSEcCtD
Acamprosate—Urticaria—Bleomycin—skin cancer	0.000895	0.00116	CcSEcCtD
Acamprosate—Haemoglobin—Docetaxel—skin cancer	0.000894	0.00116	CcSEcCtD
Acamprosate—Rhinitis—Docetaxel—skin cancer	0.000892	0.00115	CcSEcCtD
Acamprosate—Body temperature increased—Bleomycin—skin cancer	0.00089	0.00115	CcSEcCtD
Acamprosate—Hepatitis—Docetaxel—skin cancer	0.000889	0.00115	CcSEcCtD
Acamprosate—Haemorrhage—Docetaxel—skin cancer	0.000889	0.00115	CcSEcCtD
Acamprosate—Hypoaesthesia—Docetaxel—skin cancer	0.000885	0.00114	CcSEcCtD
Acamprosate—Confusional state—Fluorouracil—skin cancer	0.000883	0.00114	CcSEcCtD
Acamprosate—Pharyngitis—Docetaxel—skin cancer	0.000883	0.00114	CcSEcCtD
Acamprosate—Oedema peripheral—Docetaxel—skin cancer	0.000876	0.00113	CcSEcCtD
Acamprosate—Anaphylactic shock—Fluorouracil—skin cancer	0.000875	0.00113	CcSEcCtD
Acamprosate—Infection—Fluorouracil—skin cancer	0.00087	0.00112	CcSEcCtD
Acamprosate—Feeling abnormal—Dactinomycin—skin cancer	0.000866	0.00112	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000866	0.00112	CcSEcCtD
Acamprosate—Insomnia—Temozolomide—skin cancer	0.000859	0.00111	CcSEcCtD
Acamprosate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000859	0.00111	CcSEcCtD
Acamprosate—Thrombocytopenia—Fluorouracil—skin cancer	0.000857	0.00111	CcSEcCtD
Acamprosate—Visual impairment—Docetaxel—skin cancer	0.000857	0.00111	CcSEcCtD
Acamprosate—Tachycardia—Fluorouracil—skin cancer	0.000854	0.0011	CcSEcCtD
Acamprosate—Paraesthesia—Temozolomide—skin cancer	0.000853	0.0011	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—MC1R—skin cancer	0.00085	0.00739	CbGpPWpGaD
Acamprosate—Dyspnoea—Temozolomide—skin cancer	0.000847	0.00109	CcSEcCtD
Acamprosate—Somnolence—Temozolomide—skin cancer	0.000845	0.00109	CcSEcCtD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000844	0.00734	CbGpPWpGaD
Acamprosate—Dyspepsia—Temozolomide—skin cancer	0.000836	0.00108	CcSEcCtD
Acamprosate—Anorexia—Fluorouracil—skin cancer	0.000835	0.00108	CcSEcCtD
Acamprosate—Body temperature increased—Dactinomycin—skin cancer	0.00083	0.00107	CcSEcCtD
Acamprosate—Abdominal pain—Dactinomycin—skin cancer	0.00083	0.00107	CcSEcCtD
Acamprosate—Hypersensitivity—Bleomycin—skin cancer	0.00083	0.00107	CcSEcCtD
Acamprosate—Decreased appetite—Temozolomide—skin cancer	0.000826	0.00107	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Temozolomide—skin cancer	0.00082	0.00106	CcSEcCtD
Acamprosate—Hypotension—Fluorouracil—skin cancer	0.000818	0.00106	CcSEcCtD
Acamprosate—Constipation—Temozolomide—skin cancer	0.000813	0.00105	CcSEcCtD
Acamprosate—Pain—Temozolomide—skin cancer	0.000813	0.00105	CcSEcCtD
Acamprosate—Asthenia—Bleomycin—skin cancer	0.000808	0.00104	CcSEcCtD
Acamprosate—Immune system disorder—Docetaxel—skin cancer	0.000803	0.00104	CcSEcCtD
Acamprosate—Chills—Docetaxel—skin cancer	0.000798	0.00103	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000798	0.00103	CcSEcCtD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000797	0.00693	CbGpPWpGaD
Acamprosate—Pruritus—Bleomycin—skin cancer	0.000797	0.00103	CcSEcCtD
Acamprosate—Insomnia—Fluorouracil—skin cancer	0.000792	0.00102	CcSEcCtD
Acamprosate—Paraesthesia—Fluorouracil—skin cancer	0.000786	0.00102	CcSEcCtD
Acamprosate—Alopecia—Docetaxel—skin cancer	0.000786	0.00102	CcSEcCtD
Acamprosate—Feeling abnormal—Temozolomide—skin cancer	0.000783	0.00101	CcSEcCtD
Acamprosate—Dyspnoea—Fluorouracil—skin cancer	0.000781	0.00101	CcSEcCtD
Acamprosate—Mental disorder—Docetaxel—skin cancer	0.000779	0.00101	CcSEcCtD
Acamprosate—Somnolence—Fluorouracil—skin cancer	0.000778	0.00101	CcSEcCtD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000777	0.00676	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Temozolomide—skin cancer	0.000777	0.001	CcSEcCtD
Acamprosate—Malnutrition—Docetaxel—skin cancer	0.000774	0.001	CcSEcCtD
Acamprosate—Hypersensitivity—Dactinomycin—skin cancer	0.000774	0.001	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—MC1R—skin cancer	0.000772	0.00672	CbGpPWpGaD
Acamprosate—Dyspepsia—Fluorouracil—skin cancer	0.000771	0.000996	CcSEcCtD
Acamprosate—Decreased appetite—Fluorouracil—skin cancer	0.000761	0.000983	CcSEcCtD
Acamprosate—Dysgeusia—Docetaxel—skin cancer	0.000758	0.00098	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000756	0.000977	CcSEcCtD
Acamprosate—Urticaria—Temozolomide—skin cancer	0.000755	0.000975	CcSEcCtD
Acamprosate—Asthenia—Dactinomycin—skin cancer	0.000754	0.000974	CcSEcCtD
Acamprosate—GRIN2A—Post NMDA receptor activation events—HRAS—skin cancer	0.000752	0.00654	CbGpPWpGaD
Acamprosate—Body temperature increased—Temozolomide—skin cancer	0.000751	0.000971	CcSEcCtD
Acamprosate—Abdominal pain—Temozolomide—skin cancer	0.000751	0.000971	CcSEcCtD
Acamprosate—Back pain—Docetaxel—skin cancer	0.000749	0.000968	CcSEcCtD
Acamprosate—Pain—Fluorouracil—skin cancer	0.000749	0.000967	CcSEcCtD
Acamprosate—Muscle spasms—Docetaxel—skin cancer	0.000744	0.000962	CcSEcCtD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000739	0.00643	CbGpPWpGaD
Acamprosate—Feeling abnormal—Fluorouracil—skin cancer	0.000721	0.000932	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—SCN10A—skin cancer	0.00072	0.00626	CbGpPWpGaD
Acamprosate—Diarrhoea—Dactinomycin—skin cancer	0.000719	0.000929	CcSEcCtD
Acamprosate—Vomiting—Bleomycin—skin cancer	0.000716	0.000925	CcSEcCtD
Acamprosate—Anaemia—Docetaxel—skin cancer	0.000716	0.000925	CcSEcCtD
Acamprosate—Rash—Bleomycin—skin cancer	0.00071	0.000918	CcSEcCtD
Acamprosate—Dermatitis—Bleomycin—skin cancer	0.00071	0.000917	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—SCN10A—skin cancer	0.000702	0.00611	CbGpPWpGaD
Acamprosate—Hypersensitivity—Temozolomide—skin cancer	0.0007	0.000905	CcSEcCtD
Acamprosate—Urticaria—Fluorouracil—skin cancer	0.000695	0.000899	CcSEcCtD
Acamprosate—Syncope—Docetaxel—skin cancer	0.000694	0.000897	CcSEcCtD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000693	0.00603	CbGpPWpGaD
Acamprosate—Leukopenia—Docetaxel—skin cancer	0.000693	0.000896	CcSEcCtD
Acamprosate—Body temperature increased—Fluorouracil—skin cancer	0.000692	0.000894	CcSEcCtD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000687	0.00598	CbGpPWpGaD
Acamprosate—Palpitations—Docetaxel—skin cancer	0.000684	0.000884	CcSEcCtD
Acamprosate—Asthenia—Temozolomide—skin cancer	0.000682	0.000881	CcSEcCtD
Acamprosate—Loss of consciousness—Docetaxel—skin cancer	0.00068	0.000879	CcSEcCtD
Acamprosate—Cough—Docetaxel—skin cancer	0.000676	0.000873	CcSEcCtD
Acamprosate—Pruritus—Temozolomide—skin cancer	0.000672	0.000869	CcSEcCtD
Acamprosate—Convulsion—Docetaxel—skin cancer	0.000671	0.000867	CcSEcCtD
Acamprosate—Nausea—Bleomycin—skin cancer	0.000669	0.000865	CcSEcCtD
Acamprosate—Hypertension—Docetaxel—skin cancer	0.000668	0.000864	CcSEcCtD
Acamprosate—Vomiting—Dactinomycin—skin cancer	0.000668	0.000863	CcSEcCtD
Acamprosate—Rash—Dactinomycin—skin cancer	0.000662	0.000856	CcSEcCtD
Acamprosate—Chest pain—Docetaxel—skin cancer	0.000659	0.000852	CcSEcCtD
Acamprosate—Myalgia—Docetaxel—skin cancer	0.000659	0.000852	CcSEcCtD
Acamprosate—Arthralgia—Docetaxel—skin cancer	0.000659	0.000852	CcSEcCtD
Acamprosate—GRIN1—Post NMDA receptor activation events—HRAS—skin cancer	0.000656	0.00571	CbGpPWpGaD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000655	0.000846	CcSEcCtD
Acamprosate—Diarrhoea—Temozolomide—skin cancer	0.00065	0.00084	CcSEcCtD
Acamprosate—Hypersensitivity—Fluorouracil—skin cancer	0.000645	0.000833	CcSEcCtD
Acamprosate—Dry mouth—Docetaxel—skin cancer	0.000645	0.000833	CcSEcCtD
Acamprosate—GRIN2B—Post NMDA receptor activation events—HRAS—skin cancer	0.00064	0.00556	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CDK4—skin cancer	0.000638	0.00555	CbGpPWpGaD
Acamprosate—Confusional state—Docetaxel—skin cancer	0.000637	0.000823	CcSEcCtD
Acamprosate—Anaphylactic shock—Docetaxel—skin cancer	0.000632	0.000817	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—PTCH2—skin cancer	0.000631	0.00549	CbGpPWpGaD
Acamprosate—Dizziness—Temozolomide—skin cancer	0.000628	0.000812	CcSEcCtD
Acamprosate—Infection—Docetaxel—skin cancer	0.000628	0.000811	CcSEcCtD
Acamprosate—Nausea—Dactinomycin—skin cancer	0.000624	0.000806	CcSEcCtD
Acamprosate—Shock—Docetaxel—skin cancer	0.000622	0.000803	CcSEcCtD
Acamprosate—Pruritus—Fluorouracil—skin cancer	0.000619	0.0008	CcSEcCtD
Acamprosate—Thrombocytopenia—Docetaxel—skin cancer	0.000619	0.000799	CcSEcCtD
Acamprosate—Tachycardia—Docetaxel—skin cancer	0.000617	0.000797	CcSEcCtD
Acamprosate—Skin disorder—Docetaxel—skin cancer	0.000614	0.000793	CcSEcCtD
Acamprosate—GRIN1—EPHB-mediated forward signaling—HRAS—skin cancer	0.000605	0.00526	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000605	0.00526	CbGpPWpGaD
Acamprosate—Vomiting—Temozolomide—skin cancer	0.000604	0.000781	CcSEcCtD
Acamprosate—Anorexia—Docetaxel—skin cancer	0.000602	0.000778	CcSEcCtD
Acamprosate—Rash—Temozolomide—skin cancer	0.000599	0.000774	CcSEcCtD
Acamprosate—Diarrhoea—Fluorouracil—skin cancer	0.000599	0.000774	CcSEcCtD
Acamprosate—Dermatitis—Temozolomide—skin cancer	0.000599	0.000773	CcSEcCtD
Acamprosate—Headache—Temozolomide—skin cancer	0.000595	0.000769	CcSEcCtD
Acamprosate—Hypotension—Docetaxel—skin cancer	0.00059	0.000763	CcSEcCtD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—HRAS—skin cancer	0.000589	0.00512	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000589	0.00512	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—RASA1—skin cancer	0.00058	0.00504	CbGpPWpGaD
Acamprosate—Dizziness—Fluorouracil—skin cancer	0.000579	0.000748	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000576	0.000744	CcSEcCtD
Acamprosate—Insomnia—Docetaxel—skin cancer	0.000572	0.000739	CcSEcCtD
Acamprosate—Paraesthesia—Docetaxel—skin cancer	0.000567	0.000733	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—RASA1—skin cancer	0.000565	0.00491	CbGpPWpGaD
Acamprosate—Nausea—Temozolomide—skin cancer	0.000564	0.000729	CcSEcCtD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000564	0.00491	CbGpPWpGaD
Acamprosate—Dyspnoea—Docetaxel—skin cancer	0.000563	0.000728	CcSEcCtD
Acamprosate—Somnolence—Docetaxel—skin cancer	0.000562	0.000726	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—skin cancer	0.000562	0.00488	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PTGER4—skin cancer	0.000559	0.00486	CbGpPWpGaD
Acamprosate—Vomiting—Fluorouracil—skin cancer	0.000557	0.000719	CcSEcCtD
Acamprosate—Dyspepsia—Docetaxel—skin cancer	0.000556	0.000719	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—BRAF—skin cancer	0.000556	0.00483	CbGpPWpGaD
Acamprosate—Rash—Fluorouracil—skin cancer	0.000552	0.000713	CcSEcCtD
Acamprosate—Dermatitis—Fluorouracil—skin cancer	0.000551	0.000713	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—SHH—skin cancer	0.00055	0.00478	CbGpPWpGaD
Acamprosate—Decreased appetite—Docetaxel—skin cancer	0.000549	0.00071	CcSEcCtD
Acamprosate—Headache—Fluorouracil—skin cancer	0.000548	0.000709	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Docetaxel—skin cancer	0.000546	0.000705	CcSEcCtD
Acamprosate—Constipation—Docetaxel—skin cancer	0.00054	0.000698	CcSEcCtD
Acamprosate—Pain—Docetaxel—skin cancer	0.00054	0.000698	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—skin cancer	0.000522	0.00454	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTCH1—skin cancer	0.000522	0.00454	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—SMO—skin cancer	0.000522	0.00454	CbGpPWpGaD
Acamprosate—Feeling abnormal—Docetaxel—skin cancer	0.000521	0.000673	CcSEcCtD
Acamprosate—Nausea—Fluorouracil—skin cancer	0.00052	0.000672	CcSEcCtD
Acamprosate—Gastrointestinal pain—Docetaxel—skin cancer	0.000517	0.000668	CcSEcCtD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—BRAF—skin cancer	0.000517	0.00449	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000515	0.00448	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PTGER4—skin cancer	0.000508	0.00442	CbGpPWpGaD
Acamprosate—Body temperature increased—Docetaxel—skin cancer	0.0005	0.000645	CcSEcCtD
Acamprosate—Abdominal pain—Docetaxel—skin cancer	0.0005	0.000645	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000492	0.00428	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.00048	0.00417	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GLI2—skin cancer	0.000478	0.00416	CbGpPWpGaD
Acamprosate—Hypersensitivity—Docetaxel—skin cancer	0.000466	0.000602	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—MC1R—skin cancer	0.000456	0.00397	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—skin cancer	0.000456	0.00396	CbGpPWpGaD
Acamprosate—Asthenia—Docetaxel—skin cancer	0.000453	0.000586	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—GLI1—skin cancer	0.00045	0.00391	CbGpPWpGaD
Acamprosate—Pruritus—Docetaxel—skin cancer	0.000447	0.000578	CcSEcCtD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000443	0.00386	CbGpPWpGaD
Acamprosate—Diarrhoea—Docetaxel—skin cancer	0.000432	0.000559	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—skin cancer	0.000429	0.00373	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SUFU—skin cancer	0.000426	0.00371	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—BRAF—skin cancer	0.000426	0.0037	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—BRAF—skin cancer	0.000424	0.00369	CbGpPWpGaD
Acamprosate—Dizziness—Docetaxel—skin cancer	0.000418	0.00054	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—RASA1—skin cancer	0.000414	0.0036	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000404	0.00351	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—RASA1—skin cancer	0.000403	0.00351	CbGpPWpGaD
Acamprosate—Vomiting—Docetaxel—skin cancer	0.000402	0.000519	CcSEcCtD
Acamprosate—Rash—Docetaxel—skin cancer	0.000398	0.000515	CcSEcCtD
Acamprosate—Dermatitis—Docetaxel—skin cancer	0.000398	0.000514	CcSEcCtD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000396	0.00345	CbGpPWpGaD
Acamprosate—Headache—Docetaxel—skin cancer	0.000396	0.000512	CcSEcCtD
Acamprosate—GRIN2D—Neuronal System—BRAF—skin cancer	0.000396	0.00344	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000377	0.00328	CbGpPWpGaD
Acamprosate—Nausea—Docetaxel—skin cancer	0.000375	0.000485	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—TP53—skin cancer	0.000374	0.00325	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—BRAF—skin cancer	0.00037	0.00322	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—skin cancer	0.000365	0.00317	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000361	0.00314	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—BRAF—skin cancer	0.000361	0.00314	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000346	0.00301	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.00034	0.00296	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—BRAF—skin cancer	0.000325	0.00283	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SHH—skin cancer	0.000325	0.00283	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000325	0.00282	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—RASA1—skin cancer	0.000323	0.00281	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000319	0.00277	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000316	0.00275	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—HRAS—skin cancer	0.000311	0.00271	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTCH1—skin cancer	0.000308	0.00268	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SMO—skin cancer	0.000308	0.00268	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—HRAS—skin cancer	0.000303	0.00264	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PTGER4—skin cancer	0.0003	0.00261	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—BRAF—skin cancer	0.000284	0.00247	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.000279	0.00242	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—BRAF—skin cancer	0.000276	0.0024	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—skin cancer	0.000271	0.00236	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FOXO4—skin cancer	0.000265	0.0023	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000259	0.00226	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—HRAS—skin cancer	0.000256	0.00222	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—IL6—skin cancer	0.000248	0.00216	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—BRAF—skin cancer	0.000244	0.00212	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—BRAF—skin cancer	0.00024	0.00208	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—HRAS—skin cancer	0.000238	0.00207	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000226	0.00197	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—HRAS—skin cancer	0.000221	0.00192	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000221	0.00192	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—HRAS—skin cancer	0.000216	0.00188	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—BRAF—skin cancer	0.00021	0.00182	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CDK4—skin cancer	0.000203	0.00176	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—IL6—skin cancer	0.000199	0.00173	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CDK4—skin cancer	0.000198	0.00172	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—HRAS—skin cancer	0.000196	0.0017	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—HRAS—skin cancer	0.000195	0.0017	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—BRAF—skin cancer	0.000187	0.00163	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—BRAF—skin cancer	0.000184	0.0016	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—HRAS—skin cancer	0.000182	0.00158	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TERT—skin cancer	0.000177	0.00154	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—HRAS—skin cancer	0.00017	0.00148	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—HRAS—skin cancer	0.000166	0.00144	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—BRAF—skin cancer	0.000161	0.0014	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—NRAS—skin cancer	0.000158	0.00137	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—NRAS—skin cancer	0.000154	0.00134	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—HRAS—skin cancer	0.000149	0.0013	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000149	0.0013	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—NRAS—skin cancer	0.000149	0.0013	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000147	0.00127	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—HRAS—skin cancer	0.000146	0.00127	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BRAF—skin cancer	0.00014	0.00122	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KRAS—skin cancer	0.000136	0.00118	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KRAS—skin cancer	0.000133	0.00115	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—HRAS—skin cancer	0.00013	0.00113	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—KRAS—skin cancer	0.000128	0.00112	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	0.000128	0.00111	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—HRAS—skin cancer	0.000127	0.00111	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—HRAS—skin cancer	0.000116	0.00101	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NRAS—skin cancer	0.000113	0.000981	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—HRAS—skin cancer	0.000113	0.00098	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—IL6—skin cancer	0.000112	0.000978	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—HRAS—skin cancer	0.000112	0.000976	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—IL6—skin cancer	0.000111	0.000963	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—HRAS—skin cancer	0.00011	0.000958	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NRAS—skin cancer	0.00011	0.000956	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—HRAS—skin cancer	0.000109	0.000949	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—IL6—skin cancer	0.000108	0.000938	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—IL6—skin cancer	0.000104	0.000908	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KRAS—skin cancer	9.71e-05	0.000844	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—HRAS—skin cancer	9.63e-05	0.000838	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KRAS—skin cancer	9.47e-05	0.000823	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NRAS—skin cancer	8.81e-05	0.000766	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—HRAS—skin cancer	8.6e-05	0.000748	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—HRAS—skin cancer	8.45e-05	0.000734	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HRAS—skin cancer	8.25e-05	0.000718	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HRAS—skin cancer	8.05e-05	0.0007	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—IL6—skin cancer	7.9e-05	0.000687	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—IL6—skin cancer	7.7e-05	0.00067	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KRAS—skin cancer	7.58e-05	0.000659	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—HRAS—skin cancer	7.38e-05	0.000642	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—skin cancer	6.74e-05	0.000586	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HRAS—skin cancer	6.44e-05	0.00056	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—IL6—skin cancer	6.17e-05	0.000536	CbGpPWpGaD
